

AKRON CITY HOSPITAL  
DEPARTMENT OF PATHOLOGY  
AND LABORATORY MEDICINE

525 E. Market Street  
Akron, OH 44304  
(330) 375-3678

## FINAL SURGICAL PATHOLOGY REPORT

<b>NAME:</b>	<b>MECTOMY, MYA</b>	<b>MRN</b>	<b>R000011230</b>
<b>D.O.B.:</b>	<b>04/23/1970 46 Y F</b>	<b>BILLING NO.:</b>	<b>R00000012274</b>
<b>LOCATION:</b>	<b>QC</b>	<b>PROCEDURE DATE:</b>	<b>07/08/2016</b>
<b>SURGEON:</b>	<b>RAYMOND E CLARKE, MD</b>	<b>RECEIVED DATE:</b>	<b>07/08/2016</b>
<b>ATTENDING:</b>	<b>RAYMOND E CLARKE, MD</b>	<b>REPORT DATE:</b>	<b>07/12/2016</b>

COPIES TO:

### DIAGNOSIS:

UTERUS, MYOMECTOMY – LEIOMYOSARCOMA (8.5 CM) WITH MARGINAL INVOLVEMENT.

COMMENT: Immunohistochemical staining with adequate controls was performed in order to further characterize the malignant cells. The cells stain positively with desmin and SMA. They are negative for pancytokeratin, CD 10, and ER. The findings are supportive of the diagnosis of leiomyosarcoma. Please see the synoptic report for additional information.


### CANCER SYNOPTIC SUMMARY REPORT:

Specimen: Uterine mass  
Procedure: Myomectomy (intact)  
Tumor site: Anterior uterine fundus.  
Tumor size: 8.5 cm  
Histologic Type: Leiomyosarcoma.  
Histologic Grade: Not applicable.  
Involvement of cervix: Cannot be determined  
Extent of involvement of other organs: Unknown  
Margins: Unoriented margins involved by sarcoma.  
Lymph-vascular invasion: Present  
Lymph Nodes: Not submitted with specimen  
Pathologic Staging:  
    Primary Tumor: pT1b  
    Regional Lymph Nodes: pNX

AJCC Staging Data: STAGE IB

AHD/AHD

**Intradepartmental Consultation:** S MICHAEL THOMPSON, M.D.;



AMY H DEEKEN, M.D.

---

**CLINICAL INFORMATION:** Uterine mass**SPECIMEN:** SOFT TISSUE, NOS, BIOPSY

---

**GROSS DESCRIPTION:**

Received in formalin is a nodular, yellowish-tan soft tissue mass. It measures 8.5 x 5.2 x 4.4 cm in greatest dimensions. The recognizable surgical margins are inked in black. The cut surface is yellowish-tan in color with patchy areas of hemorrhage and possible necrosis. Representative sections are submitted. (10 ss, 10).AHD/AHD

**Disclaimer:** The use of one or more reagents in the above tests is regulated as an analyte specific reagent (ASR). These tests were developed and their performance characteristics determined by the clinical laboratories of Summa Health System. They have not been cleared by the US Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary.

All the above immunostains were performed on paraffin embedded tissue. Appropriate positive and negative controls were run in parallel with the patient's specimen; these controls showed expected staining pattern, with acceptable intensity of staining.

Case reviewed at Summa Akron City Hospital 525 E. Market St.Akron, OH 44304.